Summary
Atropine is a tropane alkaloid with antimuscarinic effects. It is used in the treatment of symptomatic bradycardia, as an antisialagogue, as an antidote, e.g. for poisoning with organophosphorus compounds, and topically as a mydriatic and cycloplegic.
Data on the use of atropine in pregnancy are extremely limited, but do not currently indicate an increased risk of fetal malformation. Information on other adverse pregnancy outcomes is too limited to permit an evidence-based assessment of any risk.
Atropine should not be withheld in a pregnant patient if there is a compelling clinical indication for use. Enhanced antenatal surveillance may be warranted following maternal atropine exposure and should be decided on a case-by case basis. Discussion with UKTIS is recommended in all cases of exposure to atropine at any stage of pregnancy.
This document is regularly reviewed and updated. Only use full UKTIS monographs downloaded directly from TOXBASE.org to be sure you are using the most up-to-date version. The summaries of these monographs are openly available on UKTIS.org.
Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from TOXBASE.org or UKTIS.org to ensure you are using the most up-to-date version.